Literature DB >> 16897708

Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast.

Eduardo Vottero1, Aruna Balgi, Kate Woods, Stuart Tugendreich, Teri Melese, Raymond J Andersen, A Grant Mauk, Michel Roberge.   

Abstract

Indoleamine 2,3-dioxygenase (IDO) is a tryptophan degradation enzyme that is emerging as an important drug target. IDO is expressed by many human tumors to help them escape immune detection, and it has been implicated in depression and in the formation of senile nuclear cataracts. There is a need for potent and selective IDO inhibitors for use in research and as lead compounds for drug development. We show that expression of human IDO in a Saccharomyces cerevisiae tryptophan auxotroph restricts yeast growth in the presence of low tryptophan concentrations and that inhibition of IDO activity can restore growth. We use this assay to screen for IDO inhibitors in collections of pure chemicals and crude natural extracts. We identify NSC 401366 (imidodicarbonimidic diamide, N-methyl-N'-9-phenanthrenyl-, monohydrochloride) as a potent nonindolic IDO inhibitor (Ki=1.5 +/- 0.2 microM) that is competitive with respect to tryptophan. We also use this assay to identify the active compound caulerpin from a crude algal extract. The yeast growth restoration assay is simple and inexpensive. It combines desirable attributes of cell- and target-based screens and is an attractive tool for chemical biology and drug screening.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16897708     DOI: 10.1002/biot.200600001

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  10 in total

1.  Novel 1-alkyl-tryptophan derivatives downregulate IDO1 and IDO2 mRNA expression induced by interferon-gamma in dendritic cells.

Authors:  Ting Sun; Xiang-Hua Chen; Zheng-De Tang; Jiong Cai; Xiao-Yan Wang; Shih-Chen Wang; Zhao-Long Li
Journal:  Mol Cell Biochem       Date:  2010-04-28       Impact factor: 3.396

Review 2.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

Review 3.  Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Authors:  Xiu-Xiu Wang; Si-Yu Sun; Qing-Qing Dong; Xiao-Xiang Wu; Wei Tang; Ya-Qun Xing
Journal:  Medchemcomm       Date:  2019-08-15       Impact factor: 3.597

4.  The Caulerpa pigment caulerpin inhibits HIF-1 activation and mitochondrial respiration.

Authors:  Yang Liu; J Brian Morgan; Veena Coothankandaswamy; Rui Liu; Mika B Jekabsons; Fakhri Mahdi; Dale G Nagle; Yu-Dong Zhou
Journal:  J Nat Prod       Date:  2009-12       Impact factor: 4.050

Review 5.  Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction?

Authors:  Stefan Löb; Alfred Königsrainer
Journal:  Langenbecks Arch Surg       Date:  2007-12-04       Impact factor: 3.445

Review 6.  T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase.

Authors:  David J Kahler; Andrew L Mellor
Journal:  Handb Exp Pharmacol       Date:  2009

7.  Interaction of Carthamus tinctorius lignan arctigenin with the binding site of tryptophan-degrading enzyme indoleamine 2,3-dioxygenase.

Authors:  Veronika Temml; Susanne Kuehnl; Daniela Schuster; Stefan Schwaiger; Hermann Stuppner; Dietmar Fuchs
Journal:  FEBS Open Bio       Date:  2013-09-07       Impact factor: 2.693

Review 8.  Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors.

Authors:  Bilal Zulfiqar; Amnah Mahroo; Kaenat Nasir; Rai Khalid Farooq; Nasir Jalal; Muhammad Usman Rashid; Kashif Asghar
Journal:  Onco Targets Ther       Date:  2017-01-21       Impact factor: 4.147

9.  Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay.

Authors:  Aruna D Balgi; Jun Wang; Daphne Y H Cheng; Chunlong Ma; Tom A Pfeifer; Yoko Shimizu; Hilary J Anderson; Lawrence H Pinto; Robert A Lamb; William F DeGrado; Michel Roberge
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240

Review 10.  Targeting the indoleamine 2,3-dioxygenase pathway in cancer.

Authors:  Yong Wha Moon; Joud Hajjar; Patrick Hwu; Aung Naing
Journal:  J Immunother Cancer       Date:  2015-12-15       Impact factor: 13.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.